Basic information and marketing status of Elotuzumab

Elotuzumab is an innovative humanized IgG1 monoclonal antibody developed by Bristol Myers Squibb and is mainly used to treat multiple myeloma. The drug works by specifically targeting the SLAMF7 protein, providing a new treatment option for patients with relapsed or refractory multiple myeloma.

Evolizumab has a unique mechanism of action. It can bind to the SLAMF7 protein on the surface of myeloma cells and activate natural killer (NK) cells at the same time. Directly kills tumor cells through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADCP). Studies have shown that compared with lenalidomide or pomalidomide alone, the combination of evolizumab can significantly enhance the anti-tumor activity and improve the therapeutic effect. This synergistic effect brings longer progression-free survival and higher response rates to multiple myeloma patients, making it an important treatment option for relapsed or refractory cases.

In terms of indications, evolizumab is mainly used in combination with lenalidomide and dexamethasone to treat adult patients with multiple myeloma who have received 1-3 previous treatments, or in combination with pomalidomide and dexamethasone in patients who have received at least two treatments (including lenalidomide and a proteasome inhibitor). Clinical trials have shown that the combination treatment regimen can significantly extend the progression-free survival of patients and is well tolerated. However, common adverse reactions include fatigue, diarrhea, fever, constipation, etc., with an incidence rate of more than 20% and require close monitoring during treatment.

Judging from the marketing status, evolizumab was approved in the United States on November 30, 2015 (trade name: E MPLICITI) was subsequently approved in the EU on May 11, 2016. Currently, this drug is not yet on the market in China, and it has not yet been included in the medical insurance list. There is no generic drug version of evolizumab available overseas. The price of the original drug is relatively high, about 15,000 yuan per bottle, which limits its accessibility to domestic patients. For patients who need to use it, they may need to purchase it through formal overseas medical consulting institutions or participate in clinical trials.

Overall, evolizumab, as a targeted therapy, provides new hope for patients with multiple myeloma. Its unique mechanism of action and significant clinical efficacy make it an important choice for relapsed or refractory cases. However, domestic patients currently face challenges of difficulty in obtaining drugs and high costs. In the future, with the approval of drugs in the country and the adjustment of medical insurance policies, this situation is expected to improve. For medical practitioners and patients, understanding the basic information and marketing dynamics of the drug can help provide a reference for treatment decisions.

Reference materials:https://www.drugs.com/